Abstract: A lifter assembly for actuating a needle of an automatic medication delivery device, includes a motor, a speed reduction device driven by the motor, an output shaft driven by the speed reduction device via a rigid transmission device, a driving lever configured to move the needle, the driving lever being connected to and driven by the output shaft, and a sensing device configured to sense the rotation position of the output shaft. The speed reduction device comprises a worm in mesh with a worm gear. The output shaft, the worm gear and the rigid transmission device cooperatively constitute a four-bar linkage mechanism.

Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.

Abstract: The invention provided Mucorales CotH polypeptides and encoding nucleic acid molecules. The Mucorales CotH polypeptides and encoding nucleic acids can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.

Abstract: An air control valve includes a body which includes a passage with an inlet and an outlet, and a chamber located between and communicated with the inlet and the outlet. The air control valve further includes a valve element rotatably disposed in the chamber, and a motor connected to the valve element for driving the valve element to rotate between a first position where the outlet communicates with the inlet and a second position where the valve element disconnects the outlet from the inlet.

Abstract: The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.

Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.

Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.

Abstract: A motor assembly for use in a surgical tool, has a motor and a gear train. The gear train has an output shaft, a fixed ring gear, a movable ring gear, a cover, and a multi-stage planetary gear set. Each gear stage has a sun gear, a carrier, and planet gears mounted on one side of the carrier. The planet gears are in mesh with a sun gear and either the fixed ring gear or the movable ring gear. The movable ring gear has inner teeth formed on an inner peripheral surface and one of the carriers has outer teeth formed on an outer peripheral surface.

Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragment, siRNA and vaccine compositions having or directed against a GRP78 polypeptide or an antigenic fragment of the polypeptide.

Abstract: A lifter assembly for actuating a needle of an automatic medication delivery device, includes a motor, a speed reduction device driven by the motor, an output shaft driven by the speed reduction device via a rigid transmission device, a driving lever configured to move the needle, the driving lever being connected to and driven by the output shaft, and a sensing device configured to sense the rotation position of the output shaft. The speed reduction device comprises a worm in mesh with a worm gear. The output shaft, the worm gear and the rigid transmission device cooperatively constitute a four-bar linkage mechanism.

Abstract: A dual current path LDMOSFET transistor (40) is provided which includes a substrate (400), a graded buried layer (401), an epitaxial drift region (404) in which a drain region (416) is formed, a first well region (406) in which a source region (412) is formed, a gate electrode (420) formed adjacent to the source region (412) to define a first channel region (107), and a current routing structure that includes a buried RESURF layer (408) in ohmic contact with a second well region (414) formed in a predetermined upper region of the epitaxial layer (404) so as to be completely covered by the gate electrode (420), the current routing structure being spaced apart from the first well region (406) and from the drain region (416) on at least a side of the drain region to delineate separate current paths from the source region and through the epitaxial layer.

Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.

Abstract: A dual current path LDMOSFET transistor (40) is provided which includes a substrate (400), a graded buried layer (401), an epitaxial drift region (404) in which a drain region (416) is formed, a first well region (406) in which a source region (412) is formed, a gate electrode (420) formed adjacent to the source region (412) to define a first channel region (107), and a current routing structure that includes a buried RESURF layer (408) in ohmic contact with a second well region (414) formed in a predetermined upper region of the epitaxial layer (404) so as to be completely covered by the gate electrode (420), the current routing structure being spaced apart from the first well region (406) and from the drain region (416) on at least a side of the drain region to delineate separate current paths from the source region and through the epitaxial layer.

Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.

Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.

Abstract: An energy-feedback clamping circuit of a power converter is proposed. The converter includes a transformer coupled to a full-wave rectifier circuit. The clamping circuit includes: two clamping diodes having two anodes coupled to each other at a common-anode terminal and two cathodes coupled to two terminals of a secondary winding of the transformer, a first clamping capacitor having a first terminal coupled to a cathode of a first rectifying diode of the rectifier circuit and a second terminal coupled to the common-anode terminal, a second clamping capacitor having a first terminal coupled to a connecting node of the output filtering inductor and capacitor of the rectifier circuit and a second terminal coupled to the common-anode terminal, and a converter circuit having an input terminal coupled to the second clamping capacitor and an output terminal for offering a power source.

Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing disseminated candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.

Abstract: An energy-feedback clamping circuit of a power converter is proposed. The converter includes a transformer coupled to a full-wave rectifier circuit. The clamping circuit includes: two clamping diodes having two anodes coupled to each other at a common-anode terminal and two cathodes coupled to two terminals of a secondary winding of the transformer, a first clamping capacitor having a first terminal coupled to a cathode of a first rectifying diode of the rectifier circuit and a second terminal coupled to the common-anode terminal, a second clamping capacitor having a first terminal coupled to a connecting node of the output filtering inductor and capacitor of the rectifier circuit and a second terminal coupled to the common-anode terminal, and a converter circuit having an input terminal coupled to the second clamping capacitor and an output terminal for offering a power source.